![](https://partners4access.com/wp-content/uploads/2018/08/US_Spinraza_Carton-and-Vial_29Nov16_2400px-1-300x169.jpeg)
Blogs
NICE balks at Spinraza price, rejects reimbursement in its draft guidance
By Christina Poschen, Consultant Email: [email protected] Biogen’s Spinraza, a treatment for the rare genetic disease spinal muscular atrophy (SMA) is currently making headlines for its